建议大家捐钱成立基金，然后面向全球悬赏科学家攻克HBV

a46346310

只有携带者才能把乙肝当胃病，对于真正的肝炎是比较麻烦的。

非东亚病夫

不要一开口就说钱，中国的乙肝问题不是钱，不如组织我们一亿乙肝同胞一起上街提出我们的心中诉说。让全国乙肝患者都站起来~~！老是说凑钱科研，我觉得是在骗钱。

a46346310

有钱肯定好办事，国家是有钱，但怎么分配使用是个问题。国家真有钱，每个人都盖一套房子，都不用抱怨房价高了。中国的钱只是看上去数量大罢了。一亿同胞，上街。大哥，理智点，现在都强制用人单位不得体检乙肝，目的是为保护不必要的歧视。

lifflefield

乙型肝炎，已经有这么强大疫苗和药物了。 只要环境和饮食控制的好，乙肝病毒迟早绝迹于人类。
这也就是为什么，现在没人继续研究乙肝病毒了，几乎都认为可以消灭乙肝病毒了。
  观点在于： 只要非感染人群注射疫苗，感染人群服用抗病毒药，100-200年之内，乙肝自然就耗干了，也就是说，从人类整体看来，乙肝其实也被攻克，疫苗和药物都有。所以，乙肝的前景惨淡，不会有国家大力投入金钱和时间。
  恰恰艾滋病，没有疫苗和良好药物，而且高危，自然投入的多，同时，药物能治疗艾滋病，就能部分治疗乙肝，故而，大家不需要投入大量金钱在乙肝病毒上，而是放在艾滋病上，自然能够一药二吃。 研究出好的抗艾滋病药物，就能给乙肝用。
  拉米夫定，恩替卡位，都是从艾滋病研发的，现在看来，对乙肝非常好啊，对不对

StephenW

回复 lifflefield 的帖子

恩替卡位 is not active against HIV.

a46346310

乙型肝炎，已经有这么强大疫苗和药物了。   问题是病毒总会变异。

lifflefield

StephenW 发表于 2012-3-25 16:33
回复 lifflefield 的帖子

恩替卡位 is not active against HIV.

No. entecavir 是从抑制艾滋病研发的，它可以抑制艾滋病毒。只是它的药效有多好的问题？
Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication

lifflefield

a46346310 发表于 2012-3-25 16:38
乙型肝炎，已经有这么强大疫苗和药物了。   问题是病毒总会变异。

现在研究是：为什么病毒总会变异？ 现在答案就是APOBEC3家族。所以，病毒如果不在这个家族作用下，没有那么高的突变率。
不要总是想当然，按照以往的经验判断病毒总要变异，而是应想到如果不让病毒变异。
现在的研发，集中在阻止病毒变异中，这些ideas就是来自APOBEC3家族。
  把HBV感染APOBEC3缺陷的家族，突变比例大幅下降，这就是我们寻找的答案之一

StephenW

回复 lifflefield 的帖子

No. entecavir 是从抑制艾滋病研发的，它可以抑制艾滋病毒。只是它的药效有多好的问题？
Entecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses. We observed that entecavir led to a consistent 1-log10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication.

I know the paper you that you are quoting from. I find it difficult to understand how it can be "potent" yet only "partial" inhibitor of HIV replaction.
The following is from Wikipedia:
USES Entecavir is used to treat chronic hepatitis B. It also helps prevent the hepatitis B virus from multiplying and infecting new liver cells. Entecavir is also indicated for the treatment of chronic hepatitis B in adults with HIV/AIDS infection. However, entecavir is not active against HIV.

History

• 1992: SQ-34676 at Squibb as part of anti-herpes virus program[3]
• 1997: BMS 200475 developed at BMS pharmaceutical research institute as antiviral nucleoside analogue à Activity demonstrated against HBV, HSV-1, HCMV, VZV in cell lines & no or little activity against HIV or influenza[4]
• Superior activity observed against HBV pushed research towards BMS 200475, its base analogues and its enantiomer against HBV in HepG2.2.15 cell line[4]
• Comparison to other NAs, proven more selective potent inhibitor of HBV by virtue of being Guanine NA[5]
• 1998: Inhibition of hepadnaviral polymerases was demonstrated in vitro in comparison to a number of NAs-TP[6]
• Metabolic studies showed more efficient phosphorylation to triphosphate active form[7]
• 3 year treatment of woodchuck model of CHB à sustained antiviral efficacy and prolonged life spans without detectable emergence of resistance[8]
• Efficacy # LVD resistant HBV replication in vitro[9]
• Superior activity compared to LVD invivo for both HBeAg + & HBeAg- patients[10][11]
• Efficacy in LVD refractory CHB patients[12]
  

混也是生活

支持，如果行的话我也会捐的最少一千。